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Abstract
YAC128 Huntington’s disease (HD) transgenic mice accumulate less manganese (Mn) in the striatum relative to wild-type
(WT) littermates. We hypothesized that Mn and mutant Huntingtin (HTT) would exhibit gene-environment interactions at the
level of neurochemistry and neuronal morphology. Twelve-week-old WT and YAC128 mice were exposed to MnCl2-4H2O
(50 mg/kg) on days 0, 3 and 6. Striatal medium spiny neuron (MSN) morphology, as well as levels of dopamine (DA) and its
metabolites (which are known to be sensitive to Mn-exposure), were analyzed at 13 weeks (7 days from initial exposure) and
16 weeks (28 days from initial exposure). No genotype-dependent differences in MSN morphology were apparent at 13
weeks. But at 16 weeks, a genotype effect was observed in YAC128 mice, manifested by an absence of the wild-type age-
dependent increase in dendritic length and branching complexity. In addition, genotype-exposure interaction effects were
observed for dendritic complexity measures as a function of distance from the soma, where only YAC128 mice were
sensitive to Mn exposure. Furthermore, striatal DA levels were unaltered at 13 weeks by genotype or Mn exposure, but at 16
weeks, both Mn exposure and the HD genotype were associated with quantitatively similar reductions in DA and its
metabolites. Interestingly, Mn exposure of YAC128 mice did not further decrease DA or its metabolites versus YAC128
vehicle exposed or Mn exposed WT mice. Taken together, these results demonstrate Mn-HD disease-toxicant interactions at
the onset of striatal dendritic neuropathology in YAC128 mice. Our results identify the earliest pathological change in
striatum of YAC128 mice as being between 13 to 16 weeks. Finally, we show that mutant HTT suppresses some Mn-
dependent changes, such as decreased DA levels, while it exacerbates others, such as dendritic pathology.
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Introduction
Huntington’s disease (HD) is an autosomal dominant inherited
disease caused by expansion of a CAG triplet-repeat within the
first exon of the Huntingtin (HTT) gene [1]. The primary
neuropathology in HD is loss of striatal, followed by cortical
neurons [2]. HD causes proliferative and/or degenerative changes
in striatal medium spiny neurons (MSNs) as evidenced by post-
mortem studies [3,4,5]. Changes in MSN morphology precede
gross striatal neuron loss [5]. Analysis of MSN morphology can
identify early neuropathology prior to death of MSNs and further
loss of striatal neurons. Although CAG repeat length is inversely
related to the age of disease-onset in humans, it only accounts for
about 60% of the variability in disease onset [6,7,8,9,10].
Environmental and/or other genetic factors account for the
remaining variability in disease onset and therefore may accelerate
or slow the age of disease onset and progression [11,12,13,14].
Metal toxicity and disruption in metal homeostasis (e.g. iron,
copper, zinc and manganese (Mn)) has been associated with many
neurodegenerative diseases including Parkinson’s disease, Hun-
tington’s disease and Alzheimer’s disease [15,16,17]. Here we
explore the possibility that exposure to Mn may modulate HD
pathophysiology.
Mn is an essential trace metal that is critical for many
physiological processes including reproduction, formation of
connective tissue and bone and normal brain function including
neurotransmitter synthesis and metabolism [18,19,20,21]. Expo-
sure to high Mn levels causes neurotoxicity, especially in brain
regions where Mn preferentially accumulates including the globus
pallidus, striatum, substantia nigra and the subthalamic nucleus
[22,23]. Rodent studies examining MSN morphology following
Mn exposure found a decrease in total dendritic length and spine
number [24]. Striatal dopamine (DA) neurotransmitter levels are
decreased in some, but not all, animal models of Mn neurotoxicity
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known to cause motor dysfunction in humans, non-human
primates and rodents [22,23,33,34,35,36]. Since the basal ganglia,
including the striatum are a common target for both HD
neuropathology and Mn accumulation, this provides the oppor-
tunity to observe a disease-toxicant interaction.
Data previously published by our group shows that following
Mn exposure the YAC128 HD mouse model exhibits decreased
striatal accumulation of Mn relative to wild-type (WT) mice [37].
This phenomenon was selectively found in the corpus striatum, the
most vulnerable brain region in HD, months before detectable
neurodegenerative pathological changes [37,38]. In vitro work
showed that a striatal cell line expressing mutant HTT
(STHdh
Q111/Q111) also accumulated less Mn upon exposure,
exhibit a basal Mn deficiency under normal culture conditions and
were resistant to Mn cytotoxicity relative to wild-type striatal cells
(STHdh
Q7/Q7) [37,39,40]. Based on these studies, we hypothe-
sized that Mn exposure could suppress striatal phenotypes in the
YAC128 mice caused by an HD-dependent Mn handling deficit.
Furthermore, we hypothesized that YAC128 mice would exhibit
diminished Mn toxicity phenotypes. An alternative hypothesis was
also considered, that expression of the toxic mutant HTT protein
in YAC128 animals could interact with striatal Mn neurotoxicity
to elicit or enhance changes in dendritic morphology or dopamine
neurochemistry. Here we test these two alternative hypotheses by
examining MSN architecture and striatal DA content following
Mn exposure in WT and YAC128 mice at 3 months of age. This is
the age when the earliest detectable motor dysfunction has been
reported and is also the age at which we previously [37,38] found a
defect in striatal Mn accumulation.
Materials and Methods
Chemical Reagents
Osmium tetroxide and glutaraldehyde were obtained from
Electron Microscopy Sciences (Hatfield, PA), manganese chloride
(MnCl2) from Alfa Aesar (Ward Hill, MA), paraformaldehyde
from Fisher Scientific (Pittsburgh, PA), Phosphate Buffered Saline
(PBS) from Mediatech Inc. (Manassas, VA), isoflurane from
Phoenix Pharmaceutical Inc. (St. Joseph, MO), and all other
chemicals were obtained from Sigma Chemical Company (St.
Louis, MO).
Animal Housing and Manganese Exposure
The FVB-Tg (YAC128)53Hay/J mouse line (YAC128) was
purchased from JAX (#004938, Bar Harbor, ME) [38]. All animal
exposure protocols were approved by the Vanderbilt University
Medical Center Institutional Animal Care and Use Committee
(IACUC) and strictly adhered to in order to minimize pain. All
exposure and procedures followed NIH laboratory animal care
and use guidelines. Genotyping of the mice and confirmation of a
consistent CAG-triplet repeat length in mutant animals was
carried out by PCR according to a previously published protocol
(#004938; from JAX) [38]. Mice were distributed into exposure
groups across multiple litters and the gender in each of the groups
was balanced. The Mn exposure paradigm was adapted from the
previously published protocol [37,41]. Male C57BL/6 mice, 7–9
months old, exposed to Mn using this protocol showed a
significant increase in striatal Mn levels without significant motor
impairment on experimental day 7, 24 hours following the last Mn
exposure. Twelve-week old mice were subcutaneously (s.c.)
injected at the hind leg with vehicle (water) or MnCl2-4H2O
(50 mg/kg) on experimental day 0, 3, and 6. Mice were
subsequently used for either inductively coupled plasma mass
spectrometry (ICP-MS) analysis of striatal metals, Golgi impreg-
nation for analysis of neuron morphology or striatal neurochem-
istry analysis.
Striatal Manganese Levels
Mice were decapitated on experimental day 7 (13 weeks, 7 mice
per group) or 28 (16 weeks, 5 mice per group) and the striatum was
rapidly dissected. The striatum was then placed in liquid nitrogen
and stored at 280uC. Samples were dried in glass vials on a heat
block at 100uC for 3 days underneath a beaker turned upside
down and digested with 65–70% nitric acid for 3 hours at 90uC.
To each sample, 10 mL of 1% nitric acid was added. Next,
samples were filtered (Arcodisc, 0.45 mm HT Tuffryn membrane)
and submitted for ICP-MS analysis. A Perkin-Elmer ELAN DRC
II ICP-MS was calibrated and verified before reading the blank
(1% nitric acid). 50 mL of In-115 at a concentration of 50 mg/L
was added to each sample as an internal control. Analysis of each
sample was read with the following settings: nebulizer flow 0.9–
1 L/min, radio frequency power 1,250–1,300 W, plasma gas flow
15 L/min, lens voltage 6.5–7.5 V, auto lens on, 3 replicates per
reading, 100 ms dwell time per atomic mass unit, 1000 ms
integration time with peak hopping scan mode.
Golgi Impregnation
In this study we use the single section rapid Golgi method that
was optimized to stain MSNs [42,43]. This method produced high
quality staining without any breaks in staining or blebbing along
the dendrites (data not shown). In brief, on experimental day 7 (13
weeks, 4–5 mice per group) or day 28 (16 weeks, 5 mice per group)
the mice were deeply anesthetized with isoflurane, and transcar-
dially perfused with 15 mL 0.1 M phosphate buffer (PB) followed
by 40 ml of 2% paraformaldehyde and 2.5% glutaraldehyde in
0.1 M PB. The brains were removed from the skulls and post-fixed
for 3 hours at room temperature. Vibratome sections were cut in
the coronal plane at 150 mm. The single-section Golgi silver
impregnation method was previously described [42,43]. The
sections were incubated in 1% osmium tetroxide for 20–
40 minutes, transferred to 3.5% potassium dichromate and
incubated overnight. The sections were then incubated in silver
nitrate between two slides for 4–6 hours. Sections were washed in
water, mounted on 0.5% gelatin coated slides, dehydrated and
cleared and coverslipped.
Neuron Reconstruction and Analysis
Golgi-impregnated striatal medium spiny neurons were recon-
structed under 606 magnification using the NeuroLucida
(MicroBrightfield, Inc., Williston, VT) system. One researcher,
blinded to genotype and exposure conditions, selected, traced and
analyzed the neurons. Four to six neurons were traced per animal
and were selected for tracing based on the following strict criteria:
location in the striatum (Bregma +0.14 mm to +0.86 mm), soma
and dendrites must be fully impregnated without beading or
breaks in staining along the dendrite, and must have at least 2
primary dendrites and reach the 3
rd branch order. Neurons were
analyzed with NeuroExplorer (MicroBrightfield, Inc., Williston,
VT). Morphometric characteristics were either averaged over the
entire neuron (total neuron measures) or analyzed as a function of
distance from the soma. Dendritic length and spine number are
summed over the entire dendritic tree to give total dendritic length
and total spine number, respectively. Total spine density is the
number of spines per 10 mm. The point of each dendrite
branching is termed a node. Therefore, the total number of nodes
is the total number of branch points summed across the dendritic
tree. The total number of ends refers to the number of dendrite
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center of the soma were used to analyze morphometric features as
a function of distance from the soma (Sholl analysis) [44].
Branching complexity was measured by tallying the number of
dendrites that cross each of the concentric circles (intersections).
The space in between each of the concentric circles creates a shell
in which morphologic features, such as dendrite length, spine
number and spine density were measured. This information
provides a more detailed view of neuron morphology.
Dopamine neurochemistry
Mice were euthanized at week 13 or 16 by decapitation. The
striatum was rapidly dissected, placed in liquid nitrogen and stored
at 280uC. Samples were submitted to the Center for Molecular
Neuroscience/Kennedy Center Neurochemistry Core Lab at
Vanderbilt University for measurement of dopamine and related
metabolites (n=4–6 mice per group) by high-performance liquid
chromatography (HPLC).
Data Analysis
Univariate, multivariate and repeated measures analysis of
variance (ANOVA) followed by post-hoc analysis using Fisher’s
LSD multiple comparison test were performed using PASW
Statistics 18 (SPSS, Inc, Chicago, IL). Grubb’s outlier test was used
prior to statistical analysis to find and eliminate outliers in data
with the significance of alpha set to p,0.05. Striatal Mn levels,
total neuron measures and striatal neurochemistry were assessed
by multivariate ANOVA with genotype, exposure and age (when
appropriate) as fixed factors. Genotype, exposure, age (when
appropriate) and radius were assigned as fixed factors in the
analysis where neuron morphologic characteristics were measured
as a function of distance from the soma. When ANOVA results
were significant, post-hoc analysis of all pairwise combinations was
used to determine statistical differences between exposure groups.
Results
YAC128 mice accumulate less Mn in the striatum
immediately following exposure
The striatum represents a target region for Mn neurotoxicity
and also degeneration in HD [2,3,5,22,23]. Accordingly, studies
were carried out to address the effect of mutant HTT and Mn
toxicity on striatal MSN morphology and striatal neurotransmitter
content in 13 and 16 week old YAC128 and WT mice. Twelve-
week old mice were exposed to vehicle (Veh, s.c.) or Mn (50 mg/
kg MnCl2-4H2O, s.c.) on experimental day 0, 3 and 6. Mice were
sacrificed on experimental day 7 (13 weeks postnatal) or day 28 (16
weeks postnatal) (Figure 1A). Mice were subsequently used for
either measurement of striatal metals by ICP-MS, striatal
neurochemical analysis or Golgi impregnation for analysis of
striatal MSN morphology.
Our first objective was to measure striatal Mn concentrations by
ICP-MS 24 hours (experimental day 7, 13 weeks old) and 3 weeks
(experimental day 28, 16 weeks old) following the last Mn
injection. At 13 weeks, levels of striatal Mn (Figure 1B) were
significantly increased in both Mn exposed WT and YAC128 mice
(F(1,23)=783.43, p,0.0001). There was a significant genotype6ex-
posure interaction with YAC128 mice accumulating significantly
lower levels of striatal Mn compared to WT (F(1,23)=5.33,
p,0.05), corroborating graphite furnace atomic absorbance
spectroscopy (GFAAS) results in an independent study [37]. At
16 weeks, (Figure 1C) this exposure effect persisted (F(1,16)=9.19,
p,0.01) and Mn levels in the striatum of WT mice were
dramatically reduced, but remained significantly elevated com-
Figure 1. Striatal Mn elevated in both genotypes at 13 but only in WT at week 16. A) Mn exposure paradigm. 12 week-old WT and YAC128
mice were exposed to MnCl2-4H2O (50 mg/kg s.c.) or vehicle (filled arrow) on days 0, 3, 6, and were sacrificed (open arrow) on experimental day 7 (13
weeks) or day 28 (16 weeks) for striatal Golgi impregnation or neurochemistry analysis. B) Striatal Mn levels, measured by ICP-MS, at week 13 (n=7)
are significantly higher in Mn exposed mice compared to their vehicle controls at week 13. There is a genotype6exposure interaction whereby
significantly less Mn accumulated in the YAC128-Mn exposed group compared to WT-Mn exposed mice. C) At week 16 (n=5), Mn levels dropped,
but a exposure effect still remains with Mn levels significantly higher in WT mice. Average striatal Mn concentrations +/2 SEM. Significant results of
post-hoc t-tests: **p,0.01,
##p,0.005 and ***p,0.001.
doi:10.1371/journal.pone.0031024.g001
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difference in striatal Mn levels between WT-Vehicle (WT-Veh),
YAC128-Veh and YAC128-Mn groups at 16 weeks. In addition to
Mn, other metals were simultaneously analyzed by ICP-MS in the
striatum of these mice. Striatal levels of copper (Cu) and zinc (Zn)
and other metals showed no significant differences across the
exposure groups at either time point (data not shown). These
results demonstrate that the sub-acute Mn exposure paradigm can
significantly and specifically elevate striatal Mn levels immediately
following exposure. Excess Mn was completely eliminated from
YAC128 striatum by 3 weeks post exposure, however WT mice
still had slightly elevated levels of striatal Mn.
Genotype influences neuron morphology at 16 weeks
Representative reconstructions of Golgi-impregnated MSNs are
shown in Figure 2. MSN morphology was unaffected by genotype
or Mn exposure at week 13 (Table 1, Figure S1), however changes
in neuron morphology were observed at week 16. There was a
significant main effect of genotype at 16 weeks on total dendritic
length (p,0.01), total spine density (p,0.01) and number of
dendrite endings (p,0.05) (Table 2, Figure S1). YAC128 mice in
both the Veh and Mn exposure groups exhibited shorter total
dendritic lengths compared to WT-Veh MSNs. YAC128 mice as a
group also had higher total spine densities and reduced numbers of
dendritic endings than WT mice. These data consistently show
that genotype plays a significant role in overall morphological
differences observed in MSNs at 16 weeks, while no significant
exposure or genotype6exposure interaction effects were seen at
this gross level of analysis.
Morphometric measures as a function of distance from
soma are influenced by genotype and Mn exposure
Several measures of neuron morphology as a function of
distance from the soma were examined in order to gain a detailed
understanding of the MSN morphology in these mice. Dendritic
arborization is an important morphological characteristic that
determines how the neuron integrates synaptic inputs. Sholl
analysis measures branching complexity of the neuron by tallying
the number of dendrites that intersect a series of evenly spaced
concentric circles centered at the soma [44]. At 13 weeks, there
was a significant effect of distance on dendritic branching (as
expected for Sholl analysis), but no significant interactions between
distance6genotype, distance6exposure, or three-way interaction
effects (Figure 3A and Table 3). At 16 weeks (Figure 3B and
Table 4) there was a significant effect of distance6genotype
(p=0.01) and as well as a significant interaction effect between Mn
exposure and genotype (distance6genotype6exposure interaction
effect, p,0.01). Post-hoc analysis revealed that the disease-toxicant
interaction effect is strongly driven by a difference in branching
complexity between WT-Veh and YAC-Mn mice at 16 weeks
(p,0.05), though trending differences between YAC-Mn and both
WT-Mn and YAC-Veh also contributed to the overall significance
of the Mn exposure6genotype interaction. These data strongly
suggest that the combined effect of Mn exposure and the HD
mutant genotype caused a greater decrease in dendritic branching
complexity than either factor alone.
We also examined dendrite length, spine number and spine
density as a function of distance from the soma as further measures
of dendritic arborization and synaptic integration. These mor-
phological characteristics of dendrites were measured in each shell
of the concentric circles used for Sholl analysis described above.
None of these measures showed significant differences at 13 weeks
(Figure 3A and 3C, and Table 3). Dendrite length as a function of
distance from the soma closely resembled the results from Sholl
analysis at 16 weeks (Figure 3B and 3D, Table 4). There was a
main effect of distance6genotype (p,0.0001) and a distance6
genotype6exposure interaction (p,0.019). Spine number as a
function of distance from the soma also showed distance6gen-
otype (p,0.01) and distance6genotype6exposure (p,0.0001)
effects at 16 weeks (Table 4). There were significant distance6
Figure 2. Representative reconstructions of striatal MSN in week 13 and 16 mice. Mice were exposed on day 0, 3, 6 with vehicle or MnCl2-
4H2O (50 mg/kg s.c.), sacrificed on experimental day 7 (week 13, n=4–5) or 28 (week 16, n=5) and the striatum was processed for Golgi
impregnation. Neurons were traced and analyzed using Neurolucida and Neuroexplorer, respectively (NeuroBrightField, Inc). Representative neurons
shown were selected to be within 5% of the mean total dendritic length of each exposure group.
doi:10.1371/journal.pone.0031024.g002
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(p=0.015) at 16 weeks for spine density as a function of distance
from the soma as well (Table 4). These data corroborate the
findings by Sholl analysis, and further demonstrate that disease-
toxicant interaction effects between HD and Mn exposure become
apparent 3 weeks post-exposure.
Onset of striatal neuropathology occurs by 16 weeks in
YAC128 mice
Comparing total dendritic length and total spine density
across age revealed that there was a significant effect of age for
both neuron measures and an age6genotype interaction for total
dendritic length (Table 5). While there was a significant increase
in total dendritic length in WT (Veh + Mn) MSNs from 13 to 16
weeks (p=0.002), there was no significant difference in YAC128
(Veh + Mn) MSNs at these time points (Figure 4A). Post-hoc t-
tests revealed a significant difference in total dendritic length
between WT and YAC128 groups at week 16 (p=0.007).Based
on this novel result, we decided to directly compare WT-Veh
and YAC128-Veh mice (Figure 4B). There was a significant
age6genotype interaction for total dendritic length between
WT-Veh and YAC128-Veh (p,0.05). Total dendritic length
increased in WT-Veh mice from 13 to 16 weeks (p=0.011),
while YAC128-Veh mice showed no significant difference in
total dendritic length across age. Similarly, total spine density
(Figure 4C) decreased from week 13 to 16 in both genotypes
(p,0.05). However, at 16 weeks total spine density was higher in
YAC128 MSNs compared to WT MSNs (p=0.005). Again
comparing just WT-Veh and YAC128-Veh mice total spine
density decreased from 13 to 16 weeks in WT-Veh MSNs
(p=0.001), but not in YAC128-Veh animals (Figure 4D). The
absence of an age-dependent increase in total dendritic length or
an age-dependent decrease in total spine density of MSNs in
YAC128 mice is the earliest sign of neuropathology identified to
date in this model of HD.
Given the onset of the HD phenotypes between 13 and 16
weeks by total gross morphological characteristics, we next sought
to determine if Sholl analyses of neuron morphology as a function
of age would corroborate the onset of pathology or reveal
additional Mn-exposure or genotype by Mn-exposure interaction
effects. Indeed, significant distance6age6genotype interactions for
dendritic branching, dendrite length and spine number were
Table 1. Two-way ANOVA statistics for total dendritic measures at 13 weeks.
Genotype Exposure Genotype6Exposure
Total Dendritic Length F(1,93)=0.125 F(1,93)=0.287 F(1,93)=1.855
p=0.724 p=0.593 p=0.176
Total Spine Density F(1,93)=0.001 F(1,93)=1.831 F(1,93)=1.00
p=0.978 p=0.179 p=0.320
Total Spine Number F(1,93)=0.143 F(1,93)=0.002 F(1,93)=0.902
p=0.707 p=0.966 p=0.345
Soma Area F(1,93)=0.602 F(1,93)=0.308 F(1,93)=0.126
p=0.440 p=0.581 p - 0.724
Total Nodes F(1,93)=0.019 F(1,93)=0.514 F(1,93)=1.817
p=0.892 p=0.475 p=0.181
Total Ends F(1,93)=0.154 F(1,93)=0.178 F(1,93)=1.687
p=0.696 p=0.674 p=0.197
doi:10.1371/journal.pone.0031024.t001
Table 2. Two-way ANOVA statistics for total dendritic measures at 16 weeks.
Genotype Exposure Genotype6Exposure
Total Dendritic Length F(1,109)=7.503 F(1,109)=0.669 F(1,109)=0.000
p=0.007 p=0.405 p=0.986
Total Spine Density F(1,109)=7.993 F(1,109)=0.033 F(1,109)=0.113
p=0.006 p=0.857 p=0.737
Total Spine Number F(1,109)=0.155 F(1,109)=0.136 F(1,109)=0.027
p=0.649 p=0.713 p=0.869
Soma Area F(1,109)=3.228 F(1,109)=0.324 F(1,109)=0.000
p=0.075 p=0.570 p=0.998
Total Nodes F(1,109)=2.549 F(1,109)=0.218 F(1,109)=1.695
p=0.113 p=0.641 p=0.196
Total Ends F(1,109)=4.058 F(1,109)=0.026 F(1,109)=1.668
p=0.046 p=0.871 p=0.199
doi:10.1371/journal.pone.0031024.t002
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branching, dendrite length and spine density; and significant
distance6genotype6exposure effects for dendritic length and
spine number (Table 6). Post-hoc analysis revealed that the
genotype effect was driven by a significant increase in branching
complexity between 13 and 16 weeks in WT mice (p,0.05).
Importantly, there was no significant difference between 13 and 16
week branching complexity in YAC128-Veh MSNs. Therefore,
changes in dendritic branching that normally occurred in WT-
Veh mice did not occur in YAC128-Veh mice, confirming an onset
of neuropathological changes between 13 and 16 weeks of age in
this model. Similar results were found for dendrite length as a
function of distance from the soma with WT mice having longer
dendrite lengths per shell at 16 weeks compared to 13 weeks
(p,0.05), whereas YAC128-Veh mice did not show this effect.
Finally, the genotype6exposure interaction was validated in this
expanded statistical model that included all 13 and 16 week data
points (Table 6). Together these data corroborate that subtle
neuropathological changes in MSN morphology commence as
early as 16 weeks of age and that the disease-toxicant interaction
between Mn and mutant HTT has a subtle effect on dendrite
length in YAC128 mice.
Figure 3. YAC128-Mn exposed mice have decreased branching complexity at 16 weeks. Morphological characteristics of MSNs were
assessed using the Sholl method. Concentric rings at 10 mm intervals were centered at the soma and intersections of dendrites at each radius were
counted to determine branching complexity. A) Dendritic branching complexity is not significantly different between groups at 13 weeks. B) Main
effects of distance6genotype and distance6genotype6exposure for dendritic branching complexity were observed only at 16 weeks. C) Dendrite
length as a function of distance from the soma is unaltered at 13 weeks. D) At 16 weeks, dendrite length as a function of distance from the soma is
subject to distance6genotype and distance6genotype6exposure effects.
doi:10.1371/journal.pone.0031024.g003
Table 3. Repeated measures two-way ANOVA statistics for dendritic measures as a function of distance from the soma at 13
weeks.
Distance6Genotype Distance6Exposure Distance6Genotype6Exposure
Sholl F(39, 3627)=0.877 F(39, 3627)=0.177 F(39, 3627)=0.510
p=0.687 p=1.000 p=0.995
Dendritic Length F(39, 3627)=1.013 F(39, 3627)=0.211 F(39, 3627)=0.772
p=0.448 p=1.000 p=0.845
Spine Number F(39, 3627)=0.933 F(39, 3627)=0.470 F(39, 3627)=0.741
p=0.589 p=0.998 p=0.881
Spine Density F(17, 1581)=0.299 F(17, 1581)=0.632 F(17, 1581)=0.825
p=0.997 p=0.869 p=0.665
doi:10.1371/journal.pone.0031024.t003
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genotype at 16 weeks
Striatal DA and DA metabolites, which have not been
previously reported in the YAC128 mice but have been reported
to change upon Mn exposure, were measured in the striatum at 13
and 16 weeks by HPLC. At 13 weeks, DA (Figure 5A) and its
metabolites (Figure 5B), 3,4-dihydroxyphenylacetic acid (DO-
PAC), homovanillic acid (HVA) and, 3-methoxytyramine (3-MT),
were not significantly different between genotype and exposure
groups although the DA turnover rate, measured by the DOPAC/
DA ratio (Figure 5B), was significantly affected by genotype
(p,0.05). DA turnover was reduced in YAC128-Mn compared to
WT-Mn mice (p,0.05). Overall, at 13 weeks there were no
changes in striatal DA levels, but the DA turnover rate was
significantly affected by genotype. By 16 weeks there were
significant exposure and genotype effects on DA levels in the
striatum. Significant main effects of exposure occur for DA
(Figure 5C, p,0.05), DOPAC (Figure 5D, p,0.05), and HVA
(Figure 5D, p,0.005) levels in the striatum. There were also
significant main effects of genotype on DA (p,0.03) and its
metabolites DOPAC (p,0.02) and HVA (p,0.02).
Striatal DA and its metabolites exhibited genotype and exposure
effects at 16 weeks. DA levels (Figure 5C) were reduced by Mn
exposure in WT mice (p,0.05). YAC128-Veh mice had decreased
Table 4. Repeated measures two-way ANOVA statistics for dendritic measures as a function of distance from the soma at 16
weeks.
Distance6Genotype Distance6Exposure Distance6Genotype6Exposure
Sholl F(30,2370)=1.709 F(30,2370)=0.558 F(30,2370)=1.713
p=0.0095 p=0.975 p=0.0093
Dendritic Length F(30,2370)=2.264 F(30,2370)=0.730 F(30,2370)=1.613
p=0.0001 p=0.8571 p=0.0187
Spine Number F(30,2370)=1.717 F(30,2370)=0.649 F(30,2370)=3.001
p=0.0090 p=0.9287 p,0.0001
Spine Density F(17,1853)=1.733 F(17,1853)=1.890 F(17,1853)=1.513
p=0.0315 p=0.0151 p=0.0812
doi:10.1371/journal.pone.0031024.t004
Figure 4. Onset of striatal neuropathology in YAC128 mice. A) Total dendritic length of WT mice (Veh + Mn) increased from week 13 to week
16, but was unchanged in YAC128 mice (Veh + Mn). B) Total dendritic length increased in WT-Veh mice from week 13 to week 16, but was unchanged
in YAC128-Veh mice. C) Total spine density decreased from 13 to 16 weeks in both WT mice (Veh + Mn) and YAC128 mice (Veh + Mn). YAC128 mice
had significantly higher total spine density than WT mice at 16 weeks. D) Total spine density decreased in WT-Veh mice from 13 to 16 weeks, but
there was no significant change in total spine density of YAC128-Veh mice. Week 13: n=4–5 mice per group, 4–6 neurons/animal. Week 16: n=5
mice/group, 4–6 neurons/animal. Average values +/2 SEM; p-values from post-hoc t-tests are on each graph, significant differences within each
genotype between weeks 13 and 16 are indicated in bold, significant differences within a given time point between genotypes are indicated by (**).
doi:10.1371/journal.pone.0031024.g004
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PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31024striatal DA levels (p,0.05) that were indistinguishable from WT-
Mn levels. Unlike in WT mice, Mn exposure failed to decrease DA
levels in YAC128 mice. Striatal DA levels in YAC128-Mn mice
were similar to YAC128-Veh and WT-Mn levels. DA metabolites
DOPAC and HVA (Figure 5D) were similarly affected by
genotype and Mn exposure. Mn exposure reduced DOPAC and
HVA levels in WT mice (p,0.01). Similarly, YAC128-Veh mice
had DOPAC and HVA levels reduced by approximately the same
degree as WT-Mn versus WT-Veh (p,0.05). DA metabolites in
YAC128 mice were not further affected by Mn exposure with
DOPAC and HVA levels were similar between YAC128-Mn,
YAC128-Veh and WT-Mn mice. The DOPAC and HVA
metabolite, 3-MT, was not significantly different in any group at
16 weeks (Figure 5D). The DOPAC/DA ratio was also unaltered
at 16 weeks (Figure 5D). Analysis of striatal DA neurochemistry
across time points revealed an age6exposure interaction for
DOPAC (F(1,37)=4.28, p,0.05) and HVA (F(1,37)=5.12, p,0.05).
These data revealed an effect of Mn exposure and genotype on the
nigrostriatal dopaminergic system that only occurred at the later
time point. Overall, at 16 weeks, Mn exposure reduced striatal DA
and metabolites specifically only in WT animals. Mutant HTT
reduced striatal DA and metabolites as well, relative to WT-Veh.
However, Mn exposure failed to show an effect on striatal DA and
its metabolites in YAC128 mice.
Discussion
This study identifies novel in vivo correlates of a recently
discovered gene-environment interaction between the disease-
causing allele of HTT and Mn exposure revealed by analysis of
striatal neurochemistry and MSN dendritic architecture. Addi-
tionally, we identified the age of onset for striatal dendritic
neuropathology and neurochemical phenotypes in the YAC128
HD mouse model to be between 13 and 16 weeks of postnatal life,
approximately corresponding to the age of onset for motor
phenotypes [38,45,46].
Onset of YAC128 striatal neuropathology
The full-length YAC128 HD model was utilized for these
studies because the onset of motor symptoms and neuropathol-
ogy recapitulate many aspects of the human disease [38,47].
Degenerative changes in MSN morphology have been found in
multiple HD models [48,49,50,51], however, striatal MSN
morphology has only been reported for YAC128 mice at one
month of age with no alterations identified [38,52]. Neuron
morphology studies of striatal MSNs in R6/1[48], R6/2 [50],
HD48 and HD89 [49] mice showed decreases in spine density
across branch order that were only evident in symptomatic mice
[50]. Milnerwood et al found no morphological differences in
striatal MSNs in YAC128 mice at 4 weeks of age [52]. We also
detected no morphological or neurochemical associated abnor-
malities in YAC128-Veh mice at 13 weeks (Figures 3, 4, and 5,
and Figure S1). Indeed our measurements of total dendritic
length and total spine density for the 13 week WT-Veh and
YAC128-Veh groups are nearly identical to values reported by
Milnerwood et al at 4 weeks of age (Figure S1) [52].
Morphological and neurochemical changes in the striatum of
the YAC128 mice were observed at 16 weeks. YAC128 mice
failed to show an increase in total dendritic length and dendritic
branching that was apparent in WT mice from 13 to 16 weeks
(Figure 4) indicating the onset of MSN neuropathology in
YAC128 mice between this window. YAC128 mice also failed to
show a significant decrease in total spine density at 16 weeks
(Figure 4). These data strongly suggest that the onset of dendritic
pathophysiology in MSNs of the YAC128 model is between 13
and 16 weeks of age – coinciding with the reported onset of
hyperkinetic motor behavior by open field [38]. Changes in
neuron morphology of similar magnitude in other brain regions
Figure 5. Striatal DA and metabolites are affected at week 16 by Mn exposure and genotype. A) There are no significant differences in
striatal DA levels at week 13. B) There is no difference between striatal levels of DOPAC or HVA at week 13, however there is a significant main effect
of genotype on ratio DOPAC/DA. The turnover rate of DA is significantly lower in YAC128-Mn than WT-Mn. C) At week 16 there is a significant effect
of genotype and exposure on striatal DA levels. WT-Mn, YAC128-Veh and YAC128-Mn have lower levels of striatal DA than WT-Veh mice. D) There are
also significant genotype and exposure effects on DA metabolites DOPAC and HVA at week 16. Levels of striatal DOPAC and HVA in WT-Mn, YAC128-
Veh and YAC128-Mn are significantly lower than in WT-Veh mice. Monoamine neurotransmitter and metabolite means (week 13 n=4–6 and week 16
n=3–8) are graphed +/2SEM. Significance by post-hoc t-test *p,0.05, **p,0.01 and
##p,0.005.
doi:10.1371/journal.pone.0031024.g005
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PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e31024have been reported to affect brain function [53,54]. Furthemore,
the changes in neuron morphology that we observed are similar
to reports in the literature examining the influence of age on
neuron morphology [54,55,56,57,58,59,60]. For example, there
is a 15% difference in dendritic length by sholl analysis between
2 to 18 months in rat frontal cortex [55]. Indeed, small
differences in dendritic arborization or dendritic spine density
significantly alter neuron connectivity and excitability, causing
differences in signal propagation [61,62,63,64,65]. Thus, al-
though the differences in neuron morphology we report here
may appear small, the functional consequences could be
significant [66,67,68,69].
The morphological changes that we observed in YAC128-Veh
mice at 16 weeks (Figures 3 and 4, and Figure S1) may be related
to alterations in striatal neurotransmitter content. At 16 weeks
YAC128-Veh mice had significantly lower levels of DA and its
metabolites, DOPAC and HVA, (Figure 5) compared to WT-Veh
mice. Reduced striatal DA levels and disturbances in dopaminer-
gic signaling have also been observed in the R6/1 [70] and R6/2
mouse models of HD [71,72,73,74]; however striatal DA levels
were only altered in L-DOPA treated YAC128 mice [75].
Mn exposure is associated with changes in striatal DA
neurochemistry of WT mice
There was a significant decrease in striatal DA, HVA and
DOPAC (Figure 5) at week 16 in WT-Mn mice, which was not
present at 13 weeks. Previous studies using different Mn exposure
paradigms have found similar alterations in striatal DA levels
[25,27,28,29,30,76,77], although conflicting studies have also been
reported [26,31,32,78,79,80]. The alterations in striatal DA levels
at 16 weeks may be directly related to the morphologic changes in
MSNs at the same age. For example, the decreased dendritic
complexity could either arise from or cause the reduced striatal
DA. While more detailed studies are needed to define cause-effect
relationships between neurotransmitters and the dendritic ultra-
structure, our data are consistent with other reports in the
literature of Mn neurotoxicity leading to dysfunction of the
nigrostriatal DA system [34,81,82].
HD-Mn interactions are associated with alterations in
striatal neurochemistry and MSN morphology
YAC128 mice showed less striatal Mn accumulation one day
after final Mn exposure at 13 weeks compared to WT littermates
(Figure 1). These data replicate findings from a previous study that
utilized GFAAS to measure striatal Mn levels in similarly exposed
YAC128 mice [37]. There are several potential mechanisms that
may influence the differential Mn accumulation between geno-
types; mutant HTT may interfere with import of Mn into the
striatum or increase efflux of Mn from the striatum. Additional
research is needed to determine the exact mechanism for
differential striatal Mn accumulation between YAC128 and WT
mice.
MSN morphology was significantly altered at 16 weeks by the
combination of the HD genotype and Mn exposure (Figures 3 and
4, and Tables 2 and 4). No differences in MSN morphology were
observed at 13 weeks when Mn levels were elevated (Figures 3 and
4, and Tables 1 and 3). This is not entirely surprising because
complex changes in MSN morphology, such as branching
complexity, would not be expected to occur such a short time
following exposure to a toxicant. Studies utilizing the DA
neurotoxicant 6-hydroxydopamine (6-OHDA) have shown that
changes in MSN morphology occur three weeks post-exposure
[83,84].
Mn exposure had significant effects on striatal DA neurochem-
istry in YAC128 mice (Figure 5). Changes in striatal neurochem-
istry following Mn exposure did not affect every neurotransmitter;
for example, serotonin was unaffected by Mn at both 13 and 16
weeks (data not shown) and exposure to Mn did not reduce striatal
DA levels in YAC128-Mn mice below YAC128-Veh or WT-Mn
levels at 16 weeks (Figure 5). We hypothesize that striatal DA levels
were not further reduced in YAC128-Mn mice because these
animals accumulate less striatal Mn than WT-Mn mice, thus the
decreased net Mn uptake in the striatum may ameliorate this
toxicity in the YAC128 mice – consistent with our main hypothesis
that the HD mutation would suppress Mn toxicity in the striatum.
The gene-environment interaction between mutant HTT and
Mn, however, is complex. While for the DA related phenotype it
appears the YAC128 animals may suppress Mn-dependent
changes, the same does not appear to be true for dendritic
morphology phenotypes. Indeed, YAC128 animals showed
increased sensitivity to Mn exposure for several outcome measures
of our Golgi analysis – consistent with our alternative hypothesis.
Several morphological changes in striatal MSNs at 16 weeks
including dendritic branching, dendritic length and spine number
were all more severely affected in the YAC128 animals exposed to
Mn versus the WT animals (e.g. Figure 3). Further studies need to
be carried out to better understand this recently discovered
disease-toxicant interaction. Nonetheless, our data strongly suggest
that Mn exposure has the potential to influence HD onset or
progression.
Conclusions
We set out to determine if Mn, mutant HTT or the combination
of the two would alter striatal neurochemistry or MSN
morphology. Overall, the answer is yes – but the direction and
degree of the effects and interactions were varied and depended
upon the specific phenotype being examined. Mn exposure has
chronic effects on neurochemistry. Striatal DA is significantly
reduced at 16 weeks in WT-Mn mice. However, we failed to
detect morphological alterations in MSN dendrites of WT mice
exposed to Mn at either time point. We identified the onset of
alterations in striatal neurochemistry and MSN dendritic neuro-
pathology at 16 weeks postnatal in YAC128 mice. The
neurochemical changes that we identified may promote NMDAR
excitotoxicity in the YAC128 mice. Finally, we identified in vivo
correlates of a disease-toxicant interaction as anticipated by our
previously reported in vitro interactions [37,40]. However, the
finding of both restorative (DA neurochemistry) and degenerative
effects (dendritic morphology changes) by Mn exposure on the
early YAC128 mutant phenotypes suggests caution should be
taken in determining the appropriate nutritional guidelines and
environmental exposures to Mn for HD patients. This study
presents the first insight into morphological changes in MSN in
YAC128 mice, however we do not address the functional
significance of these changes. Further investigation needs to be
completed to determine the effect of the HD-Mn interaction on
disease progression both at the neuroanatomical and behavioral
level, as well as to gain insight into targets and mechanisms of
disease modification.
Supporting Information
Figure S1 Total dendritic length and total number of
endings are reduced while total spine density is
increased in YAC compared to WT mice at 16 weeks.
A) Total dendritic length is unchanged in WT and YAC mice at
week 13. B) Total dendritic length is reduced in YAC vs WT mice
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spine density is unchanged across exposure groups at week 13. D)
The increased total spine density in YAC vs WT mice reveals a
significant main effect of genotype at week 16. E) No significant
difference in total number of endings was observed at 13 weeks. F)
Total number of endings were reduced in YAC128-Veh vs WT-
Veh mice revealing a significant genotype effect. Week 13: n=4–5
mice per group, 4–6 neurons/animal. Week 16: n=5 mice/group,
4–6 neurons/animal. Error bars indicate SEM. Significant
differences by post-hoc t-test indicated by *p,0.05.
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